Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally.
Outstanding track record with excellent balance sheet and pays a dividend.
Share Price & News
How has Roche Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ROG has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ROG exceeded the Swiss Pharmaceuticals industry which returned 2.7% over the past year.
Return vs Market: ROG exceeded the Swiss Market which returned -5.3% over the past year.
Price Volatility Vs. Market
How volatile is Roche Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIs Roche Holding AG (VTX:ROG) Excessively Paying Its CEO?
3 weeks ago | Simply Wall StRoche Holding AG (VTX:ROG) Is About To Go Ex-Dividend, And It Pays A 3.2% Yield
1 month ago | Simply Wall StHere's Why We Think Roche Holding (VTX:ROG) Is Well Worth Watching
Is Roche Holding undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ROG (CHF322.7) is trading below our estimate of fair value (CHF718.7)
Significantly Below Fair Value: ROG is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ROG is good value based on its PE Ratio (20.5x) compared to the Pharmaceuticals industry average (20.5x).
PE vs Market: ROG is poor value based on its PE Ratio (20.5x) compared to the Swiss market (16.2x).
Price to Earnings Growth Ratio
PEG Ratio: ROG is poor value based on its PEG Ratio (2.5x)
Price to Book Ratio
PB vs Industry: ROG is overvalued based on its PB Ratio (8.4x) compared to the CH Pharmaceuticals industry average (3x).
How is Roche Holding forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ROG's forecast earnings growth (8.3% per year) is above the savings rate (-0.6%).
Earnings vs Market: ROG's earnings (8.3% per year) are forecast to grow slower than the Swiss market (8.3% per year).
High Growth Earnings: ROG's earnings are forecast to grow, but not significantly.
Revenue vs Market: ROG's revenue (2.6% per year) is forecast to grow faster than the Swiss market (2.2% per year).
High Growth Revenue: ROG's revenue (2.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ROG's Return on Equity is forecast to be high in 3 years time (35.6%)
How has Roche Holding performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ROG has high quality earnings.
Growing Profit Margin: ROG's current net profit margins (21.2%) are higher than last year (17.6%).
Past Earnings Growth Analysis
Earnings Trend: ROG's earnings have grown by 6.9% per year over the past 5 years.
Accelerating Growth: ROG's earnings growth over the past year (28.5%) exceeds its 5-year average (6.9% per year).
Earnings vs Industry: ROG earnings growth over the past year (28.5%) exceeded the Pharmaceuticals industry 1.9%.
Return on Equity
High ROE: ROG's Return on Equity (39.3%) is considered high.
How is Roche Holding's financial position?
Financial Position Analysis
Short Term Liabilities: ROG's short term assets (CHF31.3B) exceed its short term liabilities (CHF24.1B).
Long Term Liabilities: ROG's short term assets (CHF31.3B) exceed its long term liabilities (CHF23.1B).
Debt to Equity History and Analysis
Debt Level: ROG's debt to equity ratio (40%) is considered high.
Reducing Debt: ROG's debt to equity ratio has reduced from 118.7% to 40% over the past 5 years.
Debt Coverage: ROG's debt is well covered by operating cash flow (155.9%).
Interest Coverage: ROG's interest payments on its debt are well covered by EBIT (39.4x coverage).
Inventory Level: ROG has a high level of physical assets or inventory.
Debt Coverage by Assets: ROG's debt is covered by short term assets (assets are 2.2x debt).
What is Roche Holding's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ROG's dividend (2.79%) is higher than the bottom 25% of dividend payers in the Swiss market (2.05%).
High Dividend: ROG's dividend (2.79%) is low compared to the top 25% of dividend payers in the Swiss market (4.44%).
Stability and Growth of Payments
Stable Dividend: ROG's dividends per share have been stable in the past 10 years.
Growing Dividend: ROG's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (57.1%), ROG's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ROG's dividends in 3 years are forecast to be well covered by earnings (43.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Severin Schwan (52yo)
Dr. Severin Schwan, Ph.D., has been Chief Executive Officer of Roche Holding AG and Roche Holdings, Inc. and Roche Molecular Systems Inc.since March 2008. Dr. Schwan has been Group Chief Executive Officer ...
CEO Compensation Analysis
Compensation vs Market: Severin's total compensation ($USD12.46M) is above average for companies of similar size in the Swiss market ($USD6.14M).
Compensation vs Earnings: Severin's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||12.08yrs||CHF12.19m||0.027% CHF73.0m|
|Chief Financial & IT Officer||9yrs||CHF5.68m||0.0033% CHF8.9m|
|Head of Investor Relations||no data||no data||no data|
|General Counsel||12.25yrs||CHF4.65m||0.0056% CHF15.4m|
|Chief Compliance Officer||no data||no data||no data|
|Head of Group Human Resources||4.08yrs||CHF3.72m||0.00051% CHF1.4m|
|Head of Genentech Research & Early Development||5.25yrs||no data||no data|
|Head of Group Media Relations||no data||no data||no data|
|Head of Middle East Sub-Region 1||no data||no data||no data|
|Head of Group M&A||no data||no data||no data|
Experienced Management: ROG's management team is seasoned and experienced (9 years average tenure).
|CEO & Executive Director||12.08yrs||CHF12.19m||0.027% CHF73.0m|
|Non-Executive Director||19.25yrs||CHF330.00k||0.00032% CHF877.6k|
|Non-Executive Director||5.25yrs||CHF330.00k||0.00012% CHF329.1k|
|Honorary Chairman||no data||no data||no data|
|Independent Vice Chairman||14.25yrs||no data||3.62% CHF9.9b|
|Non-Executive Director||9.08yrs||CHF330.00k||0.00047% CHF1.3m|
|Independent Chairman||6.25yrs||CHF5.75m||0.0029% CHF7.9m|
|Non-Executive Director||5.25yrs||CHF339.78k||no data|
|Non-Executive Independent Director||4.08yrs||CHF360.00k||0.000090% CHF246.8k|
|Non-Executive Independent Director||4.08yrs||CHF360.00k||0.00025% CHF685.6k|
Experienced Board: ROG's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Roche Holding AG's company bio, employee growth, exchange listings and data sources
- Name: Roche Holding AG
- Ticker: ROG
- Exchange: SWX
- Founded: 1896
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF274.259b
- Shares outstanding: 852.02m
- Website: https://www.roche.com
Number of Employees
- Roche Holding AG
- Konzern Hauptsitz
- Grenzacherstrasse 124
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RHHV.F||OTCPK (Pink Sheets LLC)||Yes||Non-Voting Equity Securities||US||USD||Jan 1992|
|RHHB.F||OTCPK (Pink Sheets LLC)||Bearer Shares||US||USD||Jan 1992|
|RHO5||DB (Deutsche Boerse AG)||Yes||Non-Voting Equity Securities||DE||EUR||Jan 1992|
|RO||SWX (SIX Swiss Exchange)||Bearer Shares||CH||CHF||Jan 1992|
|ROG||SWX (SIX Swiss Exchange)||Yes||Non-Voting Equity Securities||CH||CHF||Jan 1992|
|RHO||DB (Deutsche Boerse AG)||Bearer Shares||DE||EUR||Jan 1992|
|0QOK||LSE (London Stock Exchange)||Yes||Non-Voting Equity Securities||GB||CHF||Jan 1992|
|RHO||XTRA (XETRA Trading Platform)||Bearer Shares||DE||EUR||Jan 1992|
|RHO5||XTRA (XETRA Trading Platform)||Yes||Non-Voting Equity Securities||DE||EUR||Jan 1992|
|ROG N||BMV (Bolsa Mexicana de Valores)||Yes||Non-Voting Equity Securities||MX||MXN||Jan 1992|
|0QQ6||LSE (London Stock Exchange)||Bearer Shares||GB||CHF||Jan 1992|
|RHHB.Y||OTCPK (Pink Sheets LLC)||SPN ADR EACH REP 0.125 GENUS||US||USD||Aug 1992|
|RHO6||DB (Deutsche Boerse AG)||SPN ADR EACH REP 0.125 GENUS||DE||EUR||Aug 1992|
|0TDF||LSE (London Stock Exchange)||SPN ADR EACH REP 0.125 GENUS||GB||USD||Aug 1992|
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, obesity, ophthalmology, osteoporosis, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, and women’s health, as well oncology. In addition, it provides supplies a array of instruments and reagents, and test kits for use in the diverse research market. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/06 00:28|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.